The FDA has approved Gilead Sciences' lenacapavir (Yeztugo) for pre-exposure prophylaxis (PrEP) as the first twice-yearly injectable drug for HIV prevention. Clinical trials involving diverse populations demonstrated near-complete efficacy, with one study reporting zero HIV infections among cisgender women receiving the treatment, and another showing 96% reduction in infection rates compared to standard oral PrEP. This approval represents a breakthrough in adherence and convenience for HIV prevention strategies, potentially expanding PrEP access and accelerating efforts to curb the global HIV epidemic.